New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Diet,And,Dieting.,Beauty,Slim,Female,Body,Use,Tape,Measure.

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Novo Nordisk is leading the charge with Rybelsus, the only authorized oral GLP-1 drug.